Open-label, randomized study of NESP in pediatric subjects 18 years of age or younger.
Subjects will receive study drug (NESP or rHuEPO) for 28 weeks after a 2 week screening and
baseline period. During the study, procedures include bloodwork for laboratory assessments
and vital signs. Dose titration determined by hemoglobin values taken weekly during the
study. Antibody samples taken at baseline and during the end of study assessments. A physical
examination and laboratory tests will conclude the study.